AVITA Medical, Inc. (RCEL) Income Statement
RCEL 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRCEL revenue and net income
Where RCEL's revenue goes
2025Each bar shows an amount and its share of revenue. RCEL kept −67.8% of revenue as net income.
RCEL profit margins
RCEL growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +11.5% | — | — | — |
| Gross profit | +6.6% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RCEL quarterly EPS vs estimates
AVITA Medical beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.29).
RCEL income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $71.6M | $64.3M | $50.1M |
| Cost of revenue | $12.8M | $9.1M | $7.8M |
| Gross profit | $58.8M | $55.2M | $42.4M |
| Research & development | $20.8M | $20.4M | $20.8M |
| Sales, general & admin | $80.5M | $91.4M | $65.6M |
| Total operating expenses | $101.3M | $111.8M | $85.0M |
| Operating income | −$42.5M | −$56.6M | −$42.7M |
| Interest expense | $5.0M | $5.4M | $1.1M |
| Income before taxes | −$48.6M | −$61.8M | −$35.3M |
| Income taxes | $11,000 | $54,000 | $66,000 |
| Net income | −$48.6M | −$61.8M | −$35.4M |
| EBITDA | −$41.2M | −$55.3M | −$33.5M |
| EPS (diluted) | −$2.46 | −$3.33 | −$2.14 |
| Gross margin | 82.1% | 85.8% | 84.5% |
| Operating margin | −59.4% | −88.1% | −85.1% |
| Net margin | −67.8% | −96.3% | −70.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.7M | $19.3M | $17.6M | $17.1M | $18.4M | $18.5M | $18.4M | $19.5M | $15.2M | $11.1M | $14.2M |
| Cost of revenue | $3.9M | $3.5M | $3.3M | $3.2M | $3.5M | $2.8M | $2.3M | $3.2M | $2.1M | $1.5M | $1.8M |
| Gross profit | $17.8M | $15.7M | $14.3M | $13.9M | $14.9M | $15.7M | $16.1M | $16.4M | $13.1M | $9.6M | $12.4M |
| Research & development | $5.1M | $5.6M | $5.7M | $3.7M | $5.1M | $6.3M | $4.8M | $5.4M | $4.9M | $5.2M | $6.8M |
| Sales, general & admin | $19.5M | $18.9M | $19.0M | $19.3M | $21.0M | $21.2M | $21.2M | $24.7M | $23.8M | $21.6M | $18.0M |
| Total operating expenses | $24.6M | $24.5M | $24.7M | $23.0M | $26.1M | $27.5M | $26.1M | $30.2M | $28.7M | $26.8M | $24.7M |
| Operating income | −$6.9M | −$8.8M | −$10.4M | −$9.2M | −$11.1M | −$11.8M | −$10.0M | −$13.8M | −$15.6M | −$17.2M | −$12.3M |
| Interest expense | $1.5M | $1.4M | $1.2M | $1.3M | $1.3M | $1.2M | $1.3M | $1.4M | $1.3M | $1.4M | $1.1M |
| Income before taxes | −$7.6M | −$10.6M | −$11.6M | −$13.2M | −$9.9M | −$13.9M | −$11.6M | −$16.2M | −$15.4M | −$18.6M | −$7.1M |
| Income taxes | $33,000 | −$11,000 | −$17,000 | $15,000 | $4,000 | $8,000 | $19,000 | −$28,000 | $33,000 | $30,000 | $12,000 |
| Net income | −$7.7M | −$10.6M | −$11.6M | −$13.2M | −$9.9M | −$13.9M | −$11.6M | −$16.2M | −$15.4M | −$18.7M | −$7.1M |
| EBITDA | −$5.6M | −$8.6M | −$9.7M | −$11.3M | −$8.1M | −$12.1M | −$9.9M | −$14.6M | −$13.8M | −$17.1M | −$5.7M |
| EPS (diluted) | −$0.25 | −$0.48 | −$0.54 | −$0.71 | −$0.38 | −$0.83 | −$0.70 | −$0.62 | −$0.91 | −$1.10 | −$0.43 |
| Gross margin | 81.9% | 81.7% | 81.2% | 81.3% | 81.2% | 84.7% | 87.6% | 83.7% | 86.1% | 86.4% | 87.3% |
| Operating margin | −31.6% | −45.7% | −59.1% | −53.6% | −60.5% | −63.9% | −54.1% | −70.6% | −102.8% | −155.0% | −86.5% |
| Net margin | −35.3% | −55.1% | −66.0% | −77.3% | −53.9% | −74.9% | −63.0% | −82.9% | −101.3% | −168.0% | −49.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RCEL's financial statements (latest annual report filed February 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RCEL financial results
In fiscal year 2025 (ended December 31, 2025), AVITA Medical reported revenue of $71.6 million, up 11.5% from the year before. It had a net loss of $48.6 million, a net profit margin of −67.8%. Diluted earnings per share came to −$2.46.
See the RCEL stock overview for the latest quote and news, or the RCEL chart for price history and technical indicators.
RCEL income statement FAQ
What is AVITA Medical's annual revenue?
AVITA Medical reported total revenue of $71.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 11.5% from $64.3 million the previous year.
Is AVITA Medical profitable?
No. AVITA Medical reported a net loss of $48.6 million in fiscal 2025, a net profit margin of −67.8%; its operating margin was −59.4%.
What is AVITA Medical's gross margin?
AVITA Medical's gross margin was 82.1% in fiscal 2025: for every $100 of revenue, AVITA Medical kept $82 after the direct cost of its products and services.
How much does AVITA Medical spend on research and development?
AVITA Medical spent $20.8 million on research and development in fiscal 2025, 29.1% of revenue.
What are AVITA Medical's earnings per share?
AVITA Medical earned $-2.46 per diluted share in fiscal 2025, compared with $-3.33 a year earlier.
When will AVITA Medical report its next earnings?
AVITA Medical is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does AVITA Medical's fiscal year end?
AVITA Medical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 12, 2026.